IMIDAZOLINIC I1 RECEPTORS AGONIST - MOXONIDINE IN THE TREATMENT OF THE PATIENTS WITH DIABETES MELLITUS IN ASSOCIATION WITH ARTERIAL HYPERTENSION

Currently, there is a dramatic increase in the prevalence of Type 2 Diabetes Mellitus (DM) and hypertension (HTN) worldwide. Assessment of clinical, hemodynamic and biochemical features of the patients with Type 2 DM and HTN and influence of imidazolinic 11 receptor agonist- moxonidine on these parameters. An eight weeks open-label randomized trial, which included 80 patients (mean age 49.6 +/- 1.04 years) with Type 2 DM and HTN. After a wash-out period of one week and a placebo run-in period of 2 weeks, patients initiated the treatment with moxonidine 0.4 mg/24 hours for 8 weeks. Of the total number of 80 patients, 46 (57.5%) patients were diagnosed with gr. I HTN and 34 (42.5%)- with gr. II HTN. Monitoring the mean values of SBP over a period of 8 weeks of treatment with moxonidine showed a decrease of the average values of SBP from 152.8 +/- 1.0 mmHg to 133.7 +/- 1.4 mmHg, and a reduction of mean DBP values from 91.5 +/- 0.4 mmHg to 84.5 +/- 0.6 mmHg. The antihypertensive effect of long-term treatment with moxonidine 0.4 mg/24 hours was 61.8% by reaching "target" BP (SBP <140 mmHg and DBP <85 mmHg). Moxonidine significantly reduced SBP by 18.3 +/- 1.1 mHg, and DBP by 6.6 +/- 0.5 mmHg, did not influence the HR and had no effect on the glucose profile. The drug showed a low rate of side effects which confirmed the high safety and tolerability of the drug.